Concepedia

CLM94, a Novel Cyclic Amide with Anti-VEGFR-2 and Antiangiogenic Properties, Is Active against Primary Anaplastic Thyroid Cancer in Vitro and in Vivo

Alessandro Antonelli, Guido Bocci, Concettina La Motta, Silvia Martina Ferrari, Poupak Fallahi, Ilaria Ruffilli, Andrea Di Domenicantonio, Anna Fioravanti, Stefania Sartini, Michele Minuto,

The Journal of Clinical Endocrinology & Metabolism · 2012 · 56 citations · 25 references

DOIFull text

Open access

Abstract

The antitumor and antiangiogenic activity of a new "cyclic amide" compound, CLM94, is very promising in ATC, opening the way to a future clinical evaluation.

References

25

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

Francesca Carlomagno, Donata Vitagliano, Teresa Guida et al. · PubMed · 2002 · 570 citations

, , +17

A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.

Afshin Dowlati, Kelly M. Robertson, Matthew M. Cooney et al. · PubMed · 2002 · 406 citations

, , +17

Pyridone 6, A Pan-Janus–Activated Kinase Inhibitor, Induces Growth Inhibition of Multiple Myeloma Cells

Laura Pedranzini, Tobias Dechow, Marjan Berishaj et al. · Cancer Research · 2006 · 152 citations · Full text

, , +18

A Phase II Study of Imatinib in Patients with Advanced Anaplastic Thyroid Cancer

Huan Ha, Julia S. Lee, Susan G. Urba et al. · Thyroid · 2010 · 126 citations · Full text

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib

Guido Bocci, Alfredo Falcone, Antonio Fioravanti et al. · British Journal of Cancer · 2008 · 97 citations · Full text

, , +15